S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Enlivex Therapeutics Stock Forecast, Price & News

-0.46 (-7.72%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
126,758 shs
Average Volume
78,261 shs
Market Capitalization
$100.71 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ENLV News and Ratings via Email

Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Enlivex Therapeutics logo

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded on January 22, 2012 and is headquartered in Nes-Ziona, Israel.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$2.64 per share


Net Income
$-11.82 million
Pretax Margin




Free Float
Market Cap
$100.71 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.70 out of 5 stars

Medical Sector

962nd out of 1,418 stocks

Pharmaceutical Preparations Industry

472nd out of 684 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Enlivex Therapeutics (NASDAQ:ENLV) Frequently Asked Questions

Is Enlivex Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enlivex Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Enlivex Therapeutics stock.
View analyst ratings for Enlivex Therapeutics
or view top-rated stocks.

How has Enlivex Therapeutics' stock been impacted by Coronavirus?

Enlivex Therapeutics' stock was trading at $5.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ENLV stock has decreased by 4.7% and is now trading at $5.50.
View which stocks have been most impacted by COVID-19

When is Enlivex Therapeutics' next earnings date?

Enlivex Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, April 29th 2022.
View our earnings forecast for Enlivex Therapeutics

How were Enlivex Therapeutics' earnings last quarter?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) announced its earnings results on Sunday, November, 21st. The company reported ($0.19) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.02.
View Enlivex Therapeutics' earnings history

What price target have analysts set for ENLV?

1 Wall Street analysts have issued 1 year price objectives for Enlivex Therapeutics' shares. Their forecasts range from $33.00 to $33.00. On average, they expect Enlivex Therapeutics' share price to reach $33.00 in the next year. This suggests a possible upside of 500.0% from the stock's current price.
View analysts' price targets for Enlivex Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Enlivex Therapeutics' key executives?

Enlivex Therapeutics' management team includes the following people:
  • Oren Hershkovitz, Chief Executive Officer
  • Shachar Shlosberger, Chief Financial Officer
  • Dror Mevorach, Chief Scientific & Medical Officer
  • Odelia Ben-Shitrit, Head-Clinical Operations

What other stocks do shareholders of Enlivex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enlivex Therapeutics investors own include VBI Vaccines (VBIV), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Fulcrum Therapeutics (FULC), Soleno Therapeutics (SLNO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

What is Enlivex Therapeutics' stock symbol?

Enlivex Therapeutics trades on the NASDAQ under the ticker symbol "ENLV."

Who are Enlivex Therapeutics' major shareholders?

Enlivex Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Golden Green Inc. (0.11%).

Which institutional investors are selling Enlivex Therapeutics stock?

ENLV stock was sold by a variety of institutional investors in the last quarter, including Golden Green Inc..

How do I buy shares of Enlivex Therapeutics?

Shares of ENLV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enlivex Therapeutics' stock price today?

One share of ENLV stock can currently be purchased for approximately $5.50.

How much money does Enlivex Therapeutics make?

Enlivex Therapeutics has a market capitalization of $100.71 million. The company earns $-11.82 million in net income (profit) each year or ($0.98) on an earnings per share basis.

How many employees does Enlivex Therapeutics have?

Enlivex Therapeutics employs 50 workers across the globe.

What is Enlivex Therapeutics' official website?

The official website for Enlivex Therapeutics is www.enlivex.com.

Where are Enlivex Therapeutics' headquarters?

Enlivex Therapeutics is headquartered at 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR, TEL AVIV L3, 6522042.

How can I contact Enlivex Therapeutics?

Enlivex Therapeutics' mailing address is 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR, TEL AVIV L3, 6522042. The company can be reached via phone at (722) 670-8072 or via email at [email protected].

This page was last updated on 1/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.